Reasons to Hold Veeva Systems Stock in Your Portfolio for Now

Veeva Systems reported 3Q fiscal 2026 revenue up 16% YoY to $811 million, with both earnings and revenue beating the Zacks Consensus Estimate; the company also has a trailing four-quarter average earnings surprise of 8.2%. However, rising operating costs are a key overhang, with G&A up 56.1% YoY and total operating expenses up 7.9% YoY, alongside expectations for higher sales and marketing spend in fiscal 2026. Street outlook remains constructive: the fiscal 2026 EPS consensus has risen by $0.13 to $7.91, and 4Q fiscal 2026 revenue is forecast at $808.9 million (+12.2% YoY) with EPS of $1.92 (+10.3% YoY).

Analysis

VEEV still looks like the cleanest software toll road in regulated pharma, but the equity story is shifting from pure growth scarcity to proof of operating leverage. The next leg higher will come less from headline revenue and more from whether multi-cloud adoption turns into durable FCF expansion; if hiring keeps outrunning revenue, the market will treat the name as a high-quality compounder with a capped multiple rather than a premium re-rate.

The second-order winners are implementation-heavy ecosystems and interoperability partners that benefit as customers standardize across more workflows; that supports IQVIA and systems integrators, but it also means VEEV is pulling more budget into its platform and away from point solutions in CRM, quality, and clinical ops. Over 1-3 months, the key catalyst is not demand but margin commentary: another round of opex escalation would likely offset the estimate upgrade cycle and flatten the stock despite solid bookings.

Contrarian take: the market may be overpricing the AI narrative and underpricing the boring part of the business, which is workflow replacement and data gravity. That is durable, but it is not automatically margin accretive in the near term. The thesis is falsified if FY26 EPS revisions stop rising or if management signals that sales and marketing intensity remains elevated into the next print; that would suggest the current drawdown is not enough to reset valuation.

Key Decisions for Investors

• Initiate only a small tactical long in VEEV on weakness, with a 1-3 month horizon into the next earnings cycle; reward is a modest rerating if estimates keep rising, but the stop is any confirmation that opex is still growing faster than revenue.
• Use a defined-risk call spread in VEEV rather than outright stock if implied volatility is cheap; this expresses upside from multiple stabilization while limiting damage if margin expansion disappoints.
• For relative value, favor VEEV over lower-quality healthcare software names only after margin proof; until then, prefer a broader healthcare earnings basket with cleaner operating leverage such as MEDP, ISRG, or BSX on a 6-12 month horizon.
• Watch IQVIA as the secondary beneficiary of Veeva standardization; if the partnership starts to drive faster implementation and data workflow adoption, consider a long IQV/VEEV pair only if VEEV guidance remains conservative and IQV shows monetization, otherwise skip the trade.